Clinical and epidemiological overview of liver fibrosis and hepatocellular carcinoma in patients infected with the hepatitis C virus
DOI:
https://doi.org/10.33448/rsd-v9i7.4645Keywords:
Hepatitis C virus; Liver fibrosis; Hepatocellular carcinoma; Direct-acting antivirals.Abstract
About 2.4 million people die each year worldwide as a result of chronic infection with the hepatitis C virus (HCV). HCV is a worldwide problem, more than 170 million people are infected with the virus worldwide, corresponding to about 3% of the population. Some common signs for patients chronically infected with HCV are: increased liver enzyme activity and chronic liver diseases, such as fibrosis, cirrhosis, and hepatocellular carcinoma. The present study consists of a literature review, of a qualitative nature which aims to approach the main clinical and epidemiological aspects of the chronic infection caused by the HCV. HCV detection is carried out by screening for antibodies by enzyme-linked immunosorbent assay (ELISA) and screening for HCV-RNA through polymerase chain reaction (PCR). The current detection methods are not viable for all medical centers and outpatient clinics, making it necessary to develop new detection methods, since the technological apparatus for screening HCV-RNA, as well as ELISA, is a distant reality for the vast majority of the global health system. The development of direct-acting antivirals (DAAs) increased the viral response, reaching up to 92.7% success rate. It is necessary to monitor post-treatment patients, as well as to treat patients who are still affected by the virus worldwide, to ensure that there is no progression of liver fibrosis in cirrhosis, nor the development of HCC. Additionally, vigilance should be maintained for possible mutations and the emergence of viral resistance to DAAs.
References
AASLD. (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62, 932–954.
Alberti A & Piovesan S (2017). Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int, 37, 802–808.
Ali A, Nisar M, Idrees M, Rafque S & Iqbal M (2015). Expression of Hepatitis C virus core and E2 antigenic recombinant proteins and their use for development of diagnostic assays. Int J Infect Dis, 34, 84–9.
Bosman F, Carneiro F & Hruban R (2010). WHO classification of tumours of the digestive system (Vol. 4th ed).
Bruix J, Reig M & Sherman M (2016). Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology, 150, 835–53.
European Association for the Study of The Liver (2012). European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int, 32, 2–8.
Carmo RF, Aroucha D, Vasconcelos LRS et al (2016). Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV, 116–22.
Colvin HM & Mitchel AE (2010). Hepatitis and liver cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington: Institute of Medicine of the National Academies.
Coppola, N, Pisaturo, M, Sagnelli, C, et al. (2014). Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS One, 9(4), e94542.
Coppola N, Pisaturo M, Tonziello G et al (2012). Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infectious Diseases, 12, 357.
Coppola N, Pisaturo M, Zampino R et al. (2015). Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol, 21(38), 10749–59.
Cresswell F, Fisher M, Hughes D et al. (2015). Hepatitis C core antigen testing: a reliable, quick, and potentially cost-efective alternative to Hepatitis C polymerase chain reaction in diagnosing acute Hepatitis C virus infection. Clin Infect Dis, 60(2), 263–6.
D’Ambrosio R, Aghemo A, Fraquelli M et al. (2013). The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Journal of Hepatology, 59(2), 251–6.
Deniz K, Moreira RK, Yeh MM & Ferrel LD (2017). Steatohepatitis-like Changes in Focal Nodular Hyperplasia, A Finding to Distinguish From Steatohepatitic Variant of Hepatocellular Carcinoma. Am J Surg Pathol, 41, 277–81.
El-Emshaty WM et al. (2011). Diagnostics performance of an immuno assay for simultaneous detection of HCV core antigen and antibodies among haemodialysis patients. Braz J Microbiol, 42, 303–9.
El-Serag HB et al (2011). Hepatocellular carcinoma. N Engl J Med, 365(12), 1118–27.
El Kassas M, Funk AL, Salaheldin M et al. (2018). Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J. Viral Hepat, 25, 623–30.
Ferenci P, Fried M, Labrecque D et al (2010). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Journal of Clinical Gastroenterology, 44(4), 239–45.
Fisher T (2020). Available at: https://www.thermofisher.com/br/en/home/references/protocols/cell-and-tissue-analysis/elisa-protocol/general-elisa-protocol.html.
Friedman SL (2008). Mechanisms of Hepatic Fibrogenesis. Gastroenterology, 134(6), 1655–1669.
Friedman SL (2010). evolving challenges in hepatic fibrosis. Nature Publishing Group, 7(8), 425–36.
Ghany MG, Strader DB, Thomas DL & Seeff LB (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49(4), 1335–74.
Hajarizadeh B, Grebely J & Dore GJ (2013). Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol, 10(9), 553–62.
Hsu SH, Wang B, Kota J et al. (2012). Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig., 122, 2871–83.
Kanda T, Imazeki F & Yokosuka O (2010). New antiviral therapies for chronic hepatitis C. Hepatol Int, 4, 548–61.
Kanda T, Nakamoto S, Sasaki R et al. (2016). Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int J Med Sci., 13(4): 310-5.
Kanda T, Yokosuka O & Omata M (2013). Hepatitis C virus and hepatocellular carcinoma. Biology, 2, 304–16.
Karoney MJ & Siika AM (2013). Hepatitis C virus (HCV) infection in Africa: a review. The Pan African Medical Journal, 14, 44.
Kumada H, Chayama K, Rodrigues Jr L et al. (2015). Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology, 62, 1037–46.
Lavanchy D (2011). Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 17(2), 107–15.
Lin ZH, Xin YN, Dong QJ, et al. (2011). Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology, 53, 726–736.
Ly KN, Xing J, Klevens RM et al. (2012). The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine, 156(4), 271–8.
Messina JP, Humphreys I, Flaxman A et al. (2015). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 61(1), 77–87.
Torbenson MS (2017). Subtypes of Hepatocellular Carcinoma. Gastroenterol Clin North Am, 46, 365–91.
Pellicoro A, Ramachandran P, Iredale JP & Fallowfield JA (2014). Liver fibrosis and repair : immune regulation of wound healing in a solid organ. Nature Publishing Group, 14(3), 181–94.
Peng WJ, Yan JW, Wan YN et al. (2012). Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J. Clin. Immunol., 32, 1409–14.
Pereira LM, Martelli CM, Moreira RC et al. (2013). Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infectious Diseases, 13, 60.
Pereira AS, Shitsuka DM, Parreira FJ & Shitsuka R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Petrick JL, Braunlin M, Laversanne M et al. (2016). International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer, 139(7), 1534–45.
Pradere JP, Kluwe J, Minicis S et al. (2013). Hepatic Macrophages But Not Dendritic Cells Contribute to Liver Fibrosis by Promoting the Survival of Activated Hepatic Stellate Cells in Mice, 163111, 1461–73.
Rafik, M, Bakr, S, Soliman, D, et al. (2016). Characterization of diferential antibody production against Hepatitis C virus in diferent HCV infection status. Virol J, 13, 116.
Rehermann, B. & Bertoletti, A. (2015). Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology, 61(2), 712–21.
Sasaki R, Kanda, T, Nakamoto, S, et al. (2015). Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol, 7, 1125–32.
Sasaki, R, Kanda, T, Kato, N, et al. (2018). Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J. Hepatol, 10, 898–906.
Cheinquer, H, Sette, H Jr, Wolff, FH, et al. (2017). Treatment of Chronic HCV Infection with the New Direct Acting Antivirals ( DAA ): First Report of a Real World Experience in Southern Brazil, 16(5), 727–733.
Shehata, RH, Abdelmoneim, SS, Osman, OA, et al. (2017). Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients. Asian Pac. J. Cancer Prev, 18, 2395–401.
Shire, NJ, & Sherman, KE (2015). Epidemiology of Hepatitis C Virus. A Battle on New Frontiers. Gastroenterology Clinics of North America, 44(4), 699–716.
Smith, DB, Bukh, J, Kuiken, C, et al. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 59(1), 318–27.
Svegliati-Baroni G, Ridolfi F, Hannivoort R et al. (2005). Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology, 128, 1042–55.
World Health Organization. (2010). Geneva: World Health Organization. Secretariat. Viral Hepatitis. Sixty-Third World Health Assembly A63/15. Provisional Agenda Item 11.12, Provisional Agenda Item 11.12.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
